The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The Subsidiary has received one inspectional observation in Form 483
Alkem Medtech to acquire 100% stake of Bombay Ortho
Subscribe To Our Newsletter & Stay Updated
